Sharemaestro Newsreel

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial …

Lilly Sets 10 a.m. Webcast for Aug. 5 Financial Results

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026, followed by a conference call with investors and media at 10 a.m. Eastern time. A live webcast and replay of the call will be available on Lilly's …

Amundi group (SNY) reports 68.7M-share, 5.65% beneficial ownership position in Sanofi

Amundi and its subsidiary Amundi Asset Management have disclosed a beneficial ownership of 68,651,904 Sanofi common shares, representing 5.65% of the class. They report shared voting power over 36,655,093 shares and shared dispositive power over all 68,651,904 shares. A significant portion of these shares …

Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones

Pfizer is navigating a post-COVID transition, with revenue normalizing as sales of pandemic-related products decline significantly from their peak. The company is refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine, and emphasizes rebuilding sustainable revenue growth from these areas and …

Company News for July 22, 2026

Novartis AG's NVS shares grew 2.9% after reporting second-quarter 2026 revenues of $14.41 billion, beating the Zacks Consensus Estimate of $13.95 billion. Shares of General Motors Company GM gained 4.9% after reporting second-quarter 2026 earnings of $3.57 per share, beating the Zacks Consensus Estimate …

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals for an upfront cash consideration of approximately $6.3 billion, plus potential contingent value rights of up to $1.5 billion. Centessa specializes in OX2R agonists for sleep-wake disorders, with its lead candidate cleminorexton …

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts anticipate Astrazeneca (AZN) to report Q2 earnings of $2.50 per share, marking a 14.7% increase year-over-year, with revenues expected to rise by 5.9% to $15.31 billion. The consensus EPS estimate has seen a 1.1% downward revision in the past 30 days. …

Canaccord raises Abbvie stock price target to $282 on growth outlook

Canaccord Genuity increased its stock price target for Abbvie Inc. (NYSE: ABBV) to $282 from $273, maintaining a Buy rating due to strong growth prospects. The firm anticipates a solid second quarter driven by prescription trends and the strategic $10 billion acquisition of APGE, …

Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies

BluesightCoveer Image ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer's SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows Bluesight, the leader in hospital intelligence solutions, today announced a partnership with …

Former Biogen Executive to Lead Research at Formation Bio

Formation Bio has appointed former Biogen Inc. research head Michael Ehlers as its new chief scientific officer. Ehlers, a veteran in drug and biotech research, joins the AI-focused health startup which has raised over $615 million from various private and venture investors, including Sam …

ABBV Maintains Buy Rating -- Price Target Raised to $282 by Cana

Canaccord Genuity maintained a Buy rating for AbbVie (ABBV) and raised its price target from $273.00 to $282.00, reflecting confidence in the company's future performance. Despite the positive analyst outlook, GuruFocus indicates that ABBV is currently 20.3% overvalued with a GF Value™ of $212.81 …

Working capital per share of Amgen Inc. – BCS:AMGN1

This article provides the working capital per share for Amgen Inc., traded under the symbol AMGN1 on the Santiago Stock Exchange. It indicates that the market is currently closed with no trades recorded. The information is presented within the context of TradingView's financial data …

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Johnson & Johnson has announced that its OTTAVA™ Robotic Surgical System has received De Novo authorization from the U.S. FDA, making it the world’s first table-integrated soft tissue robotic system. The system is authorized for a variety of general surgery procedures and aims to …

J&J Receives FDA Approval for Soft Tissue Surgical Robot

Johnson & Johnson has received its first US regulatory authorization from the FDA for its Ottava robotic device, designed for soft tissue surgery. This approval allows J&J to enter the rapidly expanding surgical robotics market, marking the culmination of over a decade of research …

NOVARTIS AG : JP Morgan reaffirms its Buy rating

JP Morgan has reaffirmed its "Buy" rating for Novartis AG, with analyst Richard Vosser maintaining a positive recommendation. The target price for the pharmaceutical company is unchanged at CHF 135. This update comes amidst other recent analyst ratings, including Deutsche Bank maintaining a "Buy" …

Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued?

Bristol-Myers Squibb (BMY) has gained momentum following FDA acceptance of its New Drug Application for mezigdomide and an AI collaboration with Nvidia for drug discovery. The company is currently considered 3.2% undervalued with a fair value of $62.96, despite existing risks related to patent …

Cincinnati startup Enable Injections scores significant FDA win

Cincinnati-based startup Enable Injections, in collaboration with Sanofi, received FDA approval for its CirCliq device. This approval marks a significant milestone for the company, which continues to expand its hiring in the region. The firm is recognized as a local unicorn within the biotech …

Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown

Quarterly survey of 75 institutional investors active in healthcare delivers the first published, investor-assigned AI scores for 30 large-cap healthcare companies; Eli Lilly, UnitedHealth and Moderna lead Study highlights: In every healthcare subsector, 48% to 67% of investors say management overemphasizes AI relative to …

Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating

Canaccord Genuity has increased its price target for AbbVie (ABBV) to $282 from $273, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook by the analyst firm on the pharmaceutical company. AbbVie specializes in therapeutic drug research and development, …

ETFs Investing in AbbVie, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold AbbVie, Inc. stocks, providing key financial data for each. It includes details such as market value, weight of ABBV in the ETF, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, …

Danica Pension Livsforsikringsaktieselskab Invests $12.14 Million in Amgen Inc. $AMGN

Danica Pension Livsforsikringsaktieselskab has acquired a new stake in Amgen Inc. (NASDAQ:AMGN), purchasing 34,491 shares valued at approximately $12.14 million in the first quarter. This comes as Amgen reported strong Q1 earnings, surpassing analyst estimates, and received revised price targets from several Wall Street …

Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run

Gilead Sciences (GILD) has seen a significant 126.8% return over the past five years, yet its stock remains undervalued according to various metrics and valuation models. Despite its strong performance, particularly in its HIV portfolio, and a P/E ratio close to the biotech industry …

Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build

Pfizer's stock, though down over five years, appears fairly priced based on current valuation checks and a P/E ratio of 18.9x, which aligns closely with Simply Wall St's fair P/E of 19.7x. The company's recent oncology and weight-loss drug approvals are balanced by patent …

ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR

Organon Canada has announced the appointment of Dominic Bégin as its new President and Managing Director. Bégin, a founding member of Organon Canada's leadership team, will focus on expanding the company's presence, driving growth, and increasing patient access to medicines, including biosimilars. He brings …

ABN Amro Investment Solutions Cuts Holdings in Amgen Inc. $AMGN

ABN Amro Investment Solutions reduced its stake in Amgen Inc. by 18.1% in the first quarter, selling 12,829 shares and holding 58,173 shares valued at $20.47 million. Several other institutional investors also adjusted their holdings, with some increasing stakes while ABN Amro decreased its …

Novartis: The Buy Thesis Is Back (Rating Upgrade)

Amarin (AMRN) Projected to Release Earnings on Wednesday

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

$Eli Lilly and Co (LLY.US)$

This article features a brief community post by user "TACO Tariff Sheriff" on the Moomoo platform about Eli Lilly and Co (LLY.US). The post includes a disclaimer that the community content is for educational purposes only. It also showcases various market insights and thematic …

Return on assets % of Merck & Co., Inc. – BCS:MRK1

This article provides financial data for Merck & Co., Inc. (BCS:MRK1) focusing on its Return on Assets percentage. It is a data page from TradingView, indicating market status, and offers various financial metrics and community tools related to the company.

Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?

A recent court decision blocking Colorado's planned 70% price cap on Enbrel has removed a regulatory overhang for Amgen (AMGN). While a community narrative suggests Amgen is slightly overvalued at $359.98, Simply Wall St's DCF model indicates the stock is materially undervalued with an …

Novartis Number of Employees 2026 | Employee Count & Headcount Data

Novartis AG had approximately 75,497 employees worldwide as of March 2026, representing a 1.2% decline from 2023. The company is actively hiring, with 2,864 job postings in 2026, though hiring velocity has slowed. The largest employee concentrations are in the United States, India, and …

Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong

Amgen's stock has shown a 75.2% return over five years, with its current valuation presenting a mixed picture. A Discounted Cash Flow (DCF) analysis suggests a significant undervaluation of 46.5%, estimating an intrinsic value of $685 per share, based on strong future cash flow …

Earnings Preview: AstraZeneca to Report Financial Results on July 27

This article provides an earnings preview for AstraZeneca (AZN), stating that the pharmaceutical giant is scheduled to report its financial results on July 27. Investors will be closely watching for details on the company's performance, including revenue growth from new drug launches and overall …

[AIDS 2026] [Press release] Gilead & Merck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy

Gilead Sciences and Merck will present detailed outcomes from their Phase 3 ISLEND-1 and ISLEND-2 trials at AIDS 2026. The investigational once-weekly oral HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) demonstrated effectiveness in virally suppressed adults with HIV who switched from …

How Investors May Respond To AbbVie (ABBV) Securing EU Approval For Short-Acting Boey Aesthetic Toxin

AbbVie (ABBV) recently secured EU approval for Boey, a short-acting aesthetic toxin for treating glabellar lines, which broadens its aesthetics portfolio. While this approval adds incremental support, the primary drivers for AbbVie's investment narrative remain its immunology and neuroscience engines, balancing patent losses and …